Triple threat: targeted drugs + CAR-T cells aim to beat a tough leukemia
NCT ID NCT06481228
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This clinical trial is testing a new treatment approach for adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The treatment combines targeted drugs (olverembatinib and venetoclax) with reduced-intensity chemotherapy, followed by CAR-T cell therapy. The goal is to achieve deeper remission, reduce the need for multiple chemotherapy cycles, and improve survival and quality of life. The study will enroll 82 participants and track outcomes like disease-free survival and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CAR-T cells, venetoclax, and olverembatinib
What this could lead to
If successful, this approach could offer a more effective and less toxic first-line treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia, potentially improving long-term survival and quality of life.
What could go wrong
This is an early-phase study with a small number of participants (82). The combination therapy may cause unexpected side effects, and the long-term benefits are not yet proven. CAR-T cell therapy carries risks like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact